The transcription factor Twist plays vital roles during embryonic development through regulating/controlling cell migration. However, postnatally, in normal physiological settings, Twist is either not expressed or inactivated. Increasing evidence shows a strong correlation between Twist reactivation and both cancer progression and malignancy, where the transcriptional activities of Twist support cancer cells to disseminate from primary tumours and subsequently establish a secondary tumour growth in distant organs. However, it is largely unclear how this signalling programme is reactivated or what signalling pathways regulate its activity. The present review discusses recent advances in Twist regulation and activity, with a focus on phosphorylation-dependent Twist activity, potential upstream kinases and the contribution of these factors in transducing biological signals from upstream signalling complexes. The recent advances in these areas have shed new light on how phosphorylation-dependent regulation of the Twist proteins promotes or suppresses Twist activity, leading to differential regulation of Twist transcriptional targets and thereby influencing cell fate.
Introduction
Epithelial and mesenchymal cells are the two major cell types in metazoans. They display significant differences in both morphology and function. Epithelial cells grow adherently to form coherent layers that are maintained by different junctions through cell-cell interactions. They are less motile and exhibit sheet migration. Mesenchymal cells are characterized by a lack of cell-cell junctions and polarity, supporting single-cell movement and a substantially increased migratory potential. During embryonic development, particularly in gastrulation and neural crest formation, conversion from an epithelial into a mesenchymal phenotype [EMT (epithelial-mesenchymal transition)] or vice versa [MET (mesenchymal-epithelial transition)], has been widely observed, where it enables cells to perform essential functions in formation and differentiation of tissues and organs [1] . Owing to its capacity to function in tissue remodelling, EMT also plays a key role in wound healing upon tissue damage. Several signal transduction pathways have been shown to be capable of activating EMT in different physiological contexts, including TGFβ (transforming growth factor β) signalling, growth-factor-induced activation of RTKs (receptor tyrosine kinases), Wnt and Notch [2] . Indeed, induction of EMT Key words: Akt/protein kinase B (PKB), cancer metastasis, epithelial-mesenchymal transition (EMT), mitogen-activated protein kinase (MAPK), Twist phosphorylation, transforming growth factor β receptor signalling (TGFβR signalling).
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signalling often requires rigorous cross-talk between TGFβ, RTKs and PI3K (phosphoinositide 3-kinase)/PKB (protein kinase B) and others, which ensures not only a successful initiation, but also maintenance of the phenotype during transition [3] .
Downstream of these signalling pathways, EMT induction is frequently associated with up-regulation of a set of proteins such as fibronectin, vimentin and MMP-9 (matrix metalloproteinase 9) that enhance cell motility, whereas down-regulation of proteins of the intercellular junctions that are important to maintain an integrated epithelial morphology including E-cadherin (epithelial cadherin), catenins and cytokeratins is often observed. Interestingly, expression of these proteins has been found to tightly associate with a group of transcription factors including Twist, Snail, ZEB and Goosecoid, which are currently considered as potential biomarkers for EMT activation [4] . Upon activation of these transcription factors, epithelial cells often lose cell-cell contact and apical-basal polarity, but gain elevated migratory capacity. Inhibition of these transcription factors has been shown to block this process in various in vivo and ex vivo models.
Twist, a transcription factor belonging to the bHLH (basic helix-loop-helix) family, recognizes a short consensus DNA sequence, CANNTG, known as an E-box, to activate or suppress the transcription of its targets. Twist proteins are evolutionarily conserved from Drosophila to humans [5] . In humans, it has two isoforms: Twist1 and Twist2. The Twist proteins plays important roles in morphogenesis during embryonic development by regulating cell migration; knockout of Twist1 in mice is embryonic lethal [6] , and Twist2-null mice exhibit early postnatal death because of activation of multiple cytokine pathways [7, 8] . Notably, aberrant expression of Twist proteins has been extensively described in almost all types of human cancer. In a clinically relevant metastatic breast cancer mouse model, knockdown of Twist1 does not inhibit primary tumour growth; rather, it strongly suppresses the formation of metastatic tumour nodules in the lung [9] , indicating a unique role of Twist proteins in the regulation of cancer cell invasion. Apart from its role in promoting cell motility, the mechanism of how Twist proteins are activated during tumour progression is still an unanswered question.
Interference with phosphorylation of Twist1 on Thr 121 and Ser 123 causes SCS (Saethre-Chotzen syndrome)
Twist1 is expressed at an early stage of limb bud development. Deficiency of Twist1 in humans is associated with limb abnormalities, including polydactyly, brachydactyly and syndactyly, causing SCS in the clinic characterized by craniosynostosis and facial asymmetry [10] . Several point mutations near the DNA-binding domain of Twist1 have been observed in SCS patients. Interestingly, these mutations impaired the phosphorylation capacity of Thr 121 and Ser 123 by PKA (protein kinase A), which results in altered selectivity of dimerization partners, thus dysregulating limb development [11] . These two residues are highly conserved in all Twist family members, including Hand1 and Hand2, indicating a pivotal functional impact of PKAmediated Twist1 phosphorylation in controlling normal limb development.
PKB-mediated phosphorylation of Twist1 on Thr 121 and Ser 123 is required in cardiac remodelling
The PKB signalling pathway has been widely investigated in regulating heart development [12, 13] . Aberrant activation of PKB leads to collapsed heart functions due to hypertrophy [14, 15] . Not coincidently, Thr 121 and Ser 123 of Twist1 localize within a typical consensus motif that has been found in a number of PKB substrates [16] . This implies a high possibility that these two residues can be phosphorylated by PKB, probably in a context-dependent manner. Indeed, both residues can be phosphorylated by activated PKB [17] . By using transgenic mice that overexpress an unphosphorylatable mutant of Twist1 specifically in cardiomyocytes, postnatal development of heart function is severely interrupted. The mice expressing the Twist1 mutant undergo hypertrophy and show atrial and ventricular septal defects, which are not seen in mice expressing wild-type Twist1. This is very similar to the observations in mice expressing a non-phosphorylatable Hand1 mutant, another member of the Twist transcription factor family, which also show a significant hypertrophy phenotype in the first month after birth, and die after 2 months [17] .
PKB phosphorylates human Twist1 on Ser 42
The role of PKB proteins in protection of cells from apoptosis has been well established [18, 19] . Uncontrolled cell proliferation and an increased rate of cell survival in tumorigenesis closely associates with aberrant hyperactivation of PKB observed in cancer patients. By using a bioinformatics approach, our laboratory identified a PKB consensus motif located at the N-terminus, outside the bHLH domain of Twist1. Upon serum stimulation, PKB is rapidly activated and associates with significantly increased Twist1 phosphorylaion on Ser 42 in the nucleus, an effect that can be reversed by serum depletion [20] . When MCF-7 cells expressing wild-type Twist1 or unphosphorylatable mutants are exposed to γ -irradiation that triggers DNA damage inducing cell-cycle arrest, p53 expression is strongly inhibited in the cells expressing phosphorylated Twist1, an event that correlates with increased levels of Mdm2 (murine double minute 2) and decreased p21, indicating a suppressive role of phosphorylated Twist1 on p53 expression. The importance of Ser 42 phosphorylation is supported using a phospho-mimicking mutant S42E, which similarly blocks DNA-damage-induced cell-cycle arrest in MCF-7 cells. In contrast, replacing Ser 42 with alanine relieves p21 suppression, leading to apoptosis after 4 h of treatment. Similar effects are also seen when DNA double-strand breaks are introduced by treatment with adriamycin. It has been investigated extensively that Twist1 is up-regulated in many types of cancer including breast cancer, melanoma, prostate cancer, glioma. By examination of a set of tissue microarray samples containing five different types of tumour, Twist1 was shown to be ubiquitously phosphorylated on Ser 42 in all five types, but at a significantly higher ratio in breast (70%) and rectum (71%) tumours. These observations suggest an oncogenic role for Twist1 downstream of PKB signalling during cancer development, in which elevated Twist1 phosphorylation enhances the ability of cancer cells to override cell-cycle arrest induced by the stress from environmental stimuli, thereby promoting cell survival (Figure 1) . Notably, recent data also showed that up-regulation of Twist proteins protects cancer cells from oncogene-induced premature senescence [21, 22] . Thus it would be important to examine whether phosphorylated Twist proteins also act in this process. 18 and Ser 20 Up-regulated Twist1 expression has been found to closely associate with poor prognosis in patients with SCCHN (squamous cell carcinoma of the head and neck) [23, 24] . It is well known that tumour progression is tightly controlled through paracrine and autocrine signalling networks by functional interactions with cancer stroma [25] . IL-6 (interleukin 6) levels are increased in SCCHN patients and correlate with a worse clinical outcome. In addition, CK2 is activated in many types of cancer, including SCCHN [26] .
CK2 (casein kinase 2) phosphorylates Twist1 on Ser
In spite of MAPKs (mitogen-activated protein kinases) as the canonical downstream targets of IL-6 signalling, CK2 was reported to be indispensable downstream of IL-6 signalling in a context-dependent manner [27] . Interestingly, incubation of IL-6 with a set of SCCHN cell lines rapidly induces Twist1 expression that is associated with increased CK2 activity [28] . Data obtained from co-immunoprecipitation demonstrated that Twist1 physically forms a complex with CK2 upon IL-6 treatment, which is completely disrupted by adding a CK2 inhibitor. This interaction results in Twist1 phosphorylation on Ser 18 and Ser 20 , which are probably involved in proteinprotein interactions, as mutations replacing these serine residues with alanine dramatically weaken the complex formation. In an assay of protein stability, phosphorylated Twist1 has significantly prolonged half-life compared with its alanine mutants, indicating a key role for Ser 18 and Ser 20 phosphorylation in stabilizing Twist1 in vivo. This possibly explains why Twist1 expression is kept at high level in tumours. Moreover, Ser 18 and Ser 20 phosphorylation enhances OSC-19 SCCHN cell migration and invasion, which is inhibited by alanine mutation on these two residues. Taken together, these data suggest that Twist1 is a key downstream mediator in the signalling axis of IL-6/CK2, whose phosphorylation governs enhanced SCCHN cancer cell motility, at least partly due to stabilization of itself.
MAPK-mediated phosphorylation of Twist1 on Ser 68 promotes breast cancer cell invasion
One of the major activities of Twist is that it positively regulates cancer cell migration and invasion during cancer progression. Considering the pro-migratory role of Twist proteins in embryogenesis and the fact that Twist is phosphorylated at this stage, an obvious open question is whether the metastasis process is dependent on phospho-regulation of Twist under pathological conditions. The MAPK signalling pathway has been frequently shown to be hyper-activated in a number of types of cancer and correlates with increased metastatic potential [29, 30] . Downstream of MAPKs, NF-κB (nuclear factor κB) transcriptionally activates Twist1 [7, 31] , arguing for an important role for Twist proteins in NF-κB-dependent chemoresistance in clinical cancer therapy. In an in vitro kinase assay, Hong et al. [32] found that the conserved Ser 68 in Twist proteins can be phosphorylated directly by JNK (c-Jun N-terminal kinase), p38 and ERK (extracellularsignal-regulated kinase), which is crucial to protect Twist1 protein from cycloheximide-induced destabilization [32] . Ser 68 phosphorylation is associated with increased MAPK activity promoted by oncogenic Ras signalling. Interestingly, clinical data from human tumour samples showed high Ser 68 phosphorylation in ductal carcinomas that is tightly correlated with tumours displaying positive HER2 expression, but negative progesterone receptor expression. More importantly, p68 phosphorylation is required for Twist1-promoted down-regulation of epithelial junction proteins that maintain intact cell-cell contact and up-regulation of promigratory mesenchymal proteins, thus inducing a full EMT phenotype. Upon stimulation by TGFβ, Twist1 is rapidly phosphorylated on Ser 68 and phenocopies effects induced by Ras/MAPK activation, indicating that this post-translational modification is critical for breast cancer cell invasion.
Future perspectives
The growing body of data suggests that phosphorylationregulated activities of Twist proteins are crucial in development and disease. Although phosphorylation on Ser 42 has been shown in mouse embryos at E (embryonic day) 14.5 [20] , its function is still not known. Similarly, all the phosphorylation patterns of Twist need to be compared during embryogenesis to determine whether they contribute to ancient developmental processes or reflect aberrant modifications in pathological conditions. It is intriguing that the role of Twist1 in physiological settings postnatally is largely unknown. In contrast, it is dramatically reactivated during cancer development. These observations present Twist as an attractive potential therapeutic target for cancer treatment. Although several lines of evidence have shown that cancer cells can hijack elements of developmental EMT programmes to facilitate their survival and invasion, the detailed mechanisms still need to be closely investigated. For example, given the several phosphorylation sites on Twist proteins in several independent studies as discussed above, it still remains to be determined whether one or more phosphorylations are required for functional effects or whether the differential phosphorylations mediate nonredundant functions in tumour progression. As Twist phosphorylation is involved both in suppression of p53 induction and activation of the EMT programme, in addition to being a transcription factor, Twist proteins are not expected to act as transcriptional co-activators or repressors involved in two different transcriptional suppressive and active complexes in a context-dependent manner. Rather more likely is that Twist is regulated by differential phosphorylation that could control selective interactions with distinct transcription factor. Thus future studies focusing on identification of these binding proteins will shed light on the molecular mechanisms of how differential Twist phosphorylation specifically activates transcriptional targets during normal development, homoeostasis and disease.
